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Introduction Result
Discussion and Conclusion Methods
• Research Objective
The main objective of this study is to identify potent, oral small molecule inhibitors of Mpro
activity to prevent the devastating sequelae of severe COVID-19.
• Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus
disease 2019 (COVID-19), a pandemic that has resulted in nearly 2.8 M deaths and more than
127.8 M confirmed cases worldwide.1 There is an urgent need for novel drugs that target
SARS-CoV-2 and other pathogenic coronaviruses. The COVID-19 main protease (Mpro) plays a
critical role in the viral life cycle by releasing essential polypeptides for viral replication and
transcription.2 Furthermore, Mpro has several distinguishing characteristics that make it an
appealing candidate for drug development: 1) shared among all members of the Coronavirus
family, 2) absence of closely related homologous in humans, and 3) a conserved active site.3
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• Development of SARS-CoV-19 Mpro Inhibitors
A fragment-based drug design approach, based on recently reported α-ketoamide inhibitors of
Mpro, was employed for designing and synthesizing several peptidomimetic and non-
peptidomimetic compounds in 5 to 10 mg quantities. 2 Following, a stock solution of 100 mM
concentration of each compound was prepared using Dimethyl Sulfoxide (DMSO) for the
studies.
• Fluorescence Resonance Energy Transfer (FRET) assay
The compounds were initially screened at a fixed concentration of 50 μM with a 384- well
Microplate using FRET assay to evaluate their potential inhibition of Mpro. The study was
conducted using the main protease, MBP-tagged (SARS-CoV-2) Assay Kit (BPS Bioscience,
#79955-2) that contained Mpro, substrate, potent inhibitor (GC376) , and buffer. In this assay,
the fluorescence due to enzymatic cleavage of the substrate by SARS-CoV-2 Mpro was
detected and measured by BMG LABTECH CLARIOstar™, a fluorescent microplate reader, with
an excited/emission wavelength of 360 nm/460 nm, respectively. For the top inhibitors, dose-
dependent experiments were carried out to determine the IC50 by plotting the observed
scores at each dose point using variable parameter nonlinear regression in Prism GraphPad
Software.
• Analysis of physiochemical and pharmacokinetic properties
A computational analysis of the compounds' molecular properties and physicochemical
profiles was performed using SwissADME to predict their pharmacokinetic properties and
assess their suitability as possible orally active drug candidates.
• Molecular Modeling study
An in-silico molecular docking simulation of the SARS-CoV-2 Mpro crystal structure in complex
with the identified compounds was conducted using GOLD2020 and sybyl X2.1 to investigate
the crucial binding residues and potential binding modes of the compounds. The fitting scores
were measured for the different poses of the compounds and compared to the known potent
inhibitor (GC376) binding.
• X-ray Crystallography
One of the identified Mpro inhibitors, Compound 5 was co-crystallized with the protein and
the structure determined at 2.5 Å.
• FRET assay
The fragment-based drug design approach identified 168 potential Mpro inhibitors, which were
all tested for their inhibitory activity against Mpro using FRET assay. The study showed 29
compounds to exhibit lower fluorescence compared to the negative control, indicating
inhibitory activity, with three of the compounds (MCP-212, MCP-221 and MCP-256; Figure 1)
exhibiting over 50% enzymatic inhibition.
A dose-dependent FRET assay was performed for MCP-212, 221, and 256 at concentrations of
1, 5, 25, 50, 50, 75, 100, 125, 250, 500, 750 and 1000mM, to calculate the IC50 (Figure 2), which
is 131.6 μM, 57.7 μM, and 107.1 μM, respectively.
• Modeling Study
From the in-silico molecular docking simulation study, MCP-256 gave the top score and best fit
to the active site of Mpro that involves interactions with HIS 41, MET 49/165, GLU 166, PRO

















Figure 1: Chemical structures of compounds MCP-212, 221 and 256.

















































Figure 2:The IC50 plot of compounds MCP-212, 221 and 256.
• Analysis of physiochemical and pharmacokinetic properties
The in-silico evaluation of the pharmacokinetic properties revealed that all the tested
compounds comply with Lipinski’s rule of 5 (Lipinski violations = 0), where ClogP values ranged
between 2.62 and 4.39 (<5), molecular weight (MW) range 284.31-424.49 (<500), number of
H-bond acceptors (HBA) range 3-10 (≤ 10) and H-bond donors (HBD) range 1-2 (<5), suggesting
that these compounds would have favorable oral bioavailability (Table 1)








Rule of 5 
violations
MCP-212 300.31 5 1 2.62 0
MCP-221 284.31 4 1 3.01 0
MCP-256 424.49 3 2 4.39 0
Table 1: Drug likeness properties for oral bioavailability by Lipinski's rule of five
• X-ray Crystallography
The electron density map from the co-crystal structure of Mpro with one of the identified
inhibitors, Compound 5 showed potential binding of the inhibitors at the active site
(Figure 5).
Figure 5: The electron density map of Mpro complexed with Compound 5 at 2.5 Å. 
• Discussion
We have identified several promising inhibitors of SARS-CoV-2 Mpro. Further studies, e.g.,
biological, biophysical are ongoing which would help future designing of more potent inhibitors.
• Conclusion
Although vaccines are critical in mitigating the impact of the emerging corona virus, genetic
mutations can be a challenge. 4 The discovery of more strategies of inhibiting the virus, e.g.,
inhibition of main protease, is necessary to effectively target this virus.
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